Arca
Skip to content
Tools
Tools

Label Changes: Reblozyl (luspatercept-aamt)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Reblozyl label DailyMed has published, from Celgene Corporation, and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 15
  • Sections changed, version 20 to 21: 4

What changed from version 20 to version 21

Mar 12, 2026 to Nov 13, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Dosage and administrationChanged ยท 62 words added, 67 removed
  2. Adverse reactionsChanged ยท 56 words added
  3. Clinical studiesChanged ยท 26 removed
  4. Patient counseling informationChanged ยท 1 word added, 1 removed

Dosage and administration

Changed62 words added, 67 removed
68 unchanged lines
2.3 Preparation and Administration
REBLOZYL should be reconstituted and administered subcutaneously by a healthcare professional.
Reconstitute REBLOZYL with Sterile Water for Injection, USP only.
1 unchanged line
Vial Size | Amount of Sterile Water for Injection, USP required for reconstitution | Final Concentration | Deliverable Volume
25 mg vial | 0.68 mL | 25 mg/0.5 mL (50 mg/mL) | 0.5 mL
75 mg vial | 1.6 mL | 75 mg/1.5 mL | 1.5 mL
7 unchanged lines
5.Invert the vial and gently swirl in an inverted position for 30 seconds. Bring the vial back to the upright position, and let it sit for 30 seconds.
6.Repeat If needed, step 5 can be repeated up to seven more times to ensure complete reconstitution of material on the sides of the vial.
7.Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. REBLOZYL is a colorless to slightly yellow, clear to slightly opalescent solution which is free of foreign particulate matter. Do not use if undissolved product or foreign particulate matter are observed.
2 unchanged lines
Instructions for Subcutaneous Administration
Calculate the exact total dosing volume of 50reconstituted mg/mLREBLOZYL solution required for the patient.
Slowly withdraw the dosing volume of the reconstituted REBLOZYL solution from the single-dose vial(s) into a syringe. Divide doses requiring larger reconstituted volumes (i.e., greater than 1.2 mL) into separate similar volume injections and inject into separate sites. If multiple injections are required, use a new syringe and needle for each subcutaneous injection.
Slowly withdraw the dosing volume of the reconstituted REBLOZYL solution from the single-dose vial(s) into a syringe. The maximum volume per subcutaneous injection site is 2 mL.
If injection volume exceeds 2 mL, use a new syringe and needle for each subcutaneous injection. Divide volume equally between syringes.
Administer the injection subcutaneously into theseparate sites: upper arm, thigh, and/or abdomen.

Adverse reactions

Changed56 words added
19 unchanged lines
Table 7: Adverse Drug Reactions (>5%) in Patients with Beta Thalassemia Receiving REBLOZYL with a Difference Between Arms of 1% in BELIEVE Trial
Body System / | REBLOZYL (N=223) | Placebo (N=109)
Adverse Reaction | All Grades n (%) | Grades โ‰ฅ3a n (%) | All Grades n (%) | Grades โ‰ฅ3 n (%)
77 unchanged lines
a Number of patients at Grades 0-1 at baseline.
b GFR= glomerular filtration rate (mL/min).
Parameter | REBLOZYL | Epoetin Alfa
44 unchanged lines
Creatinine clearance reduced | 113 | 30 (27) | 62 | 13 (21)
MAXILUS Study (NCT06045689)
The MAXILUS study evaluated larger injection volumes (up to 2 mL). Fifty patients with very low- to intermediate- risk myelodysplastic syndromes received injection volumes greater than 1.2 mL and up to 2 mL. The increase in injection volume did not appear to increase the incidence of local or systemic immunologic adverse reactions.

Clinical studies

Changed26 removed
65 unchanged lines
Table 16: Key Efficacy Results in COMMANDS
EOT = End of treatment; HI-E = Hematologic Improvement โ€“ Erythroid Response; NE = Not Estimable; RBC-TI = red blood cell transfusion independence. a The majority of study participants (>90%) were outside of the United States and a non-U.S.-licensed epoetin alfa product was used in the control arm for such patients. Direct comparisons have not been established between REBLOZYL and U.S. licensed epoetin alfa product for the treatment of patients with anemia due to IPSS-R very low, low, or intermediate-risk myelodysplastic syndromes or MDS/MPN RS-T in ESA-naรฏve patients. b Common rate difference is based on the Mantel-Haenszel stratum weights. c Based on CMH test stratified by baseline RBC transfusion burden (< 4, โ‰ฅ 4 pRBC units), RS status (RS+, RS-) and sEPO level (โ‰ค 200, > 200 U/L). 2-sided p-value is presented. The statistical significance level at the second interim analysis is two-sided p-value 0.03.
Endpoint | REBLOZYL (N=147) | Epoetin Alfa a (N=154)
25 unchanged lines
Table 17: Baseline Disease Characteristics of Patients in MEDALIST
EPO=erythropoietin; IPSS R=International Prognostic Scoring System-Revised; ITT=intent-to-treat; MDS=myelodysplastic syndromes; RARS=refractory anemia with ring sideroblasts; RBC=red blood cell; RCMD=refractory cytopenia with multilineage dysplasia; SD=standard deviation; WHO=World Health Organization. a Time since original MDS diagnosis was defined as the number of years from the date of original diagnosis to the date of informed consent. b Baseline EPO was defined as the highest EPO value within 35 days of the first dose of study drug. c Includes MDS-RS-MLD and MDS-RS-SLD. d Includes MDS-EB-1, MDS-EB-2, and MDS-U.
Disease Characteristic | REBLOZYL (N=153) | Placebo (N=76)
41 unchanged lines

Patient counseling information

Changed1 word added, 1 removed
13 unchanged lines
REBLOZYLยฎ is a registered trademark of Celgene Corporation, a Bristol-Myers Squibb Company.
REBPI.008009

Unchanged: Indications and usage, Dosage forms and strengths, Contraindications, Warnings and precautions, Use in specific populations, Drug abuse and dependence, Description, Clinical pharmacology, Nonclinical toxicology, How supplied, Patient information, PRINCIPAL DISPLAY PANEL - 25 mg Vial Label, PRINCIPAL DISPLAY PANEL - 25 mg Vial Carton - USA, PRINCIPAL DISPLAY PANEL - 25 mg Vial Carton - Singapore, PRINCIPAL DISPLAY PANEL - 75 mg Vial Label, PRINCIPAL DISPLAY PANEL - 75 mg Vial Carton - USA, PRINCIPAL DISPLAY PANEL - 75 mg Vial Carton - Singapore.

Every version

15 versions of set 82f4d266-3f52-41eb-86ba-0abf3cf468e8, newest first.
VersionPublished on DailyMedCompareSPL file
21Nov 13, 2026Shown belowDownload .zip
20Mar 12, 2026With version 19Download .zip
19May 30, 2024With version 18Download .zip
18Sep 7, 2023With version 17Download .zip
17Oct 3, 2022With version 16Download .zip
16Aug 17, 2022With version 15Download .zip
15Jun 17, 2022With version 14Download .zip
14Nov 15, 2021With version 13Download .zip
13Sep 20, 2021With version 12Download .zip
12Sep 8, 2021With version 11Download .zip
11Nov 16, 2020With version 9Download .zip
9Apr 17, 2020With version 8Download .zip
8Jan 6, 2020With version 6Download .zip
6Nov 22, 2019With version 2Download .zip
2Nov 21, 2019First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.